FibroGen (NASDAQ:FGEN) Releases Earnings Results, Beats Expectations By $1.75 EPS

FibroGen (NASDAQ:FGEN) posted its earnings results on Thursday. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $1.75, Bloomberg Earnings reports. The company had revenue of $191.57 million during the quarter, compared to analyst estimates of $29.03 million. FibroGen had a net margin of 13.90% and a return on equity of 9.62%. FibroGen’s revenue for the quarter was up 335.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) earnings per share.

FGEN stock traded down $0.30 during trading on Friday, reaching $46.20. The company had a trading volume of 590,936 shares, compared to its average volume of 464,759. FibroGen has a 52 week low of $33.51 and a 52 week high of $62.00. The stock has a market cap of $4.01 billion, a P/E ratio of -44.85 and a beta of 1.86. The business’s 50 day moving average price is $45.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16.

A number of analysts have recently weighed in on FGEN shares. Mizuho reiterated a “buy” rating and set a $65.00 target price on shares of FibroGen in a report on Sunday. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 target price on shares of FibroGen in a report on Wednesday, May 29th. Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a report on Monday, July 29th. ValuEngine lowered shares of FibroGen from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Piper Jaffray Companies reiterated a “positive” rating and set a $40.00 target price (down from $65.00) on shares of FibroGen in a report on Monday, May 27th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $61.14.



In related news, Director Kalevi Kurkijarvi sold 6,000 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $45.22, for a total value of $271,320.00. Following the completion of the transaction, the director now directly owns 34,400 shares of the company’s stock, valued at $1,555,568. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $46.74, for a total transaction of $1,852,586.64. Following the completion of the transaction, the chief executive officer now directly owns 2,402,842 shares of the company’s stock, valued at $112,308,835.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 287,810 shares of company stock valued at $11,906,668. 8.96% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC increased its stake in shares of FibroGen by 150.0% during the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. FTB Advisors Inc. bought a new position in shares of FibroGen during the first quarter valued at approximately $27,000. Manchester Capital Management LLC bought a new position in shares of FibroGen during the first quarter valued at approximately $39,000. Cornerstone Advisors Inc. increased its stake in shares of FibroGen by 672.8% during the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 693 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in shares of FibroGen during the first quarter valued at approximately $45,000. 66.51% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: What is total return in investing?

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.